Broad, Iovance-Owned IP Around Amtagvi™ and Other TIL Therapy in Development
- >60 granted or allowed US and international patents
- Compositions of matter for TIL products
- Methods of treatment in a broad range of cancers
- Manufacturing processes
- >700 patents and applications worldwide, including major pharmaceutical markets
- Gen 2 patent rights expected to provide exclusivity into 2038
- Additional patent rights expected to provide exclusivity into 2042
This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.